Experience the full interactive Multichannel News Release by accessing the following link: https://www2.multivu.com/amgen/9292951-en-la-la-anthony-amgen-partner-to-encourage-open-dialogue-about-plaque-psoriasis.
In a newly released interactive video, La La provides an in-depth look at how plaque psoriasis has impacted both her personal and professional life. She emphasizes the importance of advocating for treatment options that suit her needs and encourages others to do the same.
La La shared her experience of trying various management methods for plaque psoriasis, such as a prescription shampoo for scalp psoriasis, which was inconvenient for her due to daily hair washing requirements. She realized the significance of openly communicating with her doctor about treatment challenges and urges individuals living with plaque psoriasis to express how the disease and treatments affect their daily lives.
Plaque psoriasis is often misunderstood as a skin condition but is actually an autoimmune disease originating as internal inflammation, manifesting as itchy, flaky patches covering varying skin areas. Research indicates a discrepancy between patient and doctor assessments of the severity of plaque psoriasis, with patients often perceiving their symptoms as more severe.
While topical treatments like creams or ointments are commonly prescribed for plaque psoriasis patches, they only alleviate symptoms and not the root cause of inflammation. These treatments are sometimes considered messy to apply by patients. Board-certified dermatologist Dr. Meagen McCusker underscores the uniqueness of each patient’s experience with plaque psoriasis and recommends discussing treatment options that target underlying inflammation with healthcare providers, considering disease severity and lifestyle factors in the decision-making process.
To engage with La La in her interactive video, access resources for facilitating discussions on plaque psoriasis treatment with healthcare providers, and learn about Otezla (apremilast), an oral treatment option, visit MomentsWithLaLa.com. It should be noted that La La is not currently undergoing treatment or using Otezla.
Amgen is dedicated to assisting plaque psoriasis patients in accessing affordable treatment options, particularly Otezla. For further details, visit Otezla.com.
Psoriasis is a chronic condition characterized by rapid skin cell buildup, leading to red, scaly, and itchy patches on the skin. Globally, approximately 125 million individuals, including over 8 million in the United States, are affected by psoriasis, with around 80% of patients having plaque psoriasis.
Otezla (apremilast) is an oral phosphodiesterase 4 inhibitor that targets cyclic adenosine monophosphate (cAMP) levels to modulate the production of inflammatory mediators. Since its FDA approval in 2014, Otezla has been prescribed to over 1 million patients worldwide for conditions such as plaque psoriasis, psoriatic arthritis, and Behçet’s Disease.
Otezla is indicated for use in adult patients with moderate to severe plaque psoriasis who are eligible for phototherapy or systemic therapy, pediatric patients aged 6 years and older with moderate to severe plaque psoriasis, adult patients with active psoriatic arthritis, and adult patients with oral ulcers associated with Behçet’s Disease.
It is crucial to note contraindications, warnings, precautions, adverse reactions, and drug interactions associated with Otezla. It is advised to consult healthcare providers before initiating treatment with Otezla.
For additional information about Amgen and their innovative medical solutions for challenging diseases, please visit Amgen.com and follow Amgen on various social media platforms.
